CLOSEOUT LETTER
Duy Drugs Inc. MARCS-CMS 542933 —
- Delivery Method:
- Electronic Mail
- Reference #:
- 20-HAFE4-WLCOL-12
- Product:
- Dietary Supplements
Drugs
- Recipient:
-
Recipient NameMr. Ricardo Mayo-Alvarez
-
Recipient TitlePresident/Owner
- Duy Drugs Inc.
1730 NW 79th Ave.
Doral, FL 33126
United States-
- doralphar@aol.com
- Issuing Office:
- Office of Human and Animal Food Operations Division IV East
United States
- (787) 729-8500
Dear Mr. Mayo-Alvarez:
The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to Warning Letter 18-HAFE4-WL-05 dated August 28, 2018. It appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Kind regards,
/S/
Edwin Ramos
Director of Compliance Branch
OHAFO, Division IV East